Share Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

PRNewsWire · JNJ · November 5, 2026

Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: PRNewsWire ↗